Home›Cardiology› Machine learning and multi-omics technologies support precision medicine in cardiovascular disease diagnosis and risk prediction
Machine learning and multi-omics technologies support precision medicine in cardiovascular disease diagnosis and risk predictionMachine Learning and Multi-Omics Improve Cardiovascular Disease Prediction
Frontiers in MedicinePublished August 13, 2026DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Note that machine learning and multi-omics can enhance cardiovascular diagnosis and personalized risk stratification.
This systematic review explores how machine learning combined with multi-omics data can advance precision medicine for cardiovascular disease. The authors synthesize evidence suggesting that these technologies provide a framework for capturing complex molecular and phenotypic data to improve clinical outcomes.
Key findings indicate that these integrated tools can assist in definitive diagnosis, early detection, differential diagnosis, and severity assessment. They may enable more noninvasive, objective, rapid, and precise evaluations. Furthermore, the technology supports comprehensive frameworks for primary and secondary prevention, short-term risk stratification, and screening of high-risk populations. These models may also facilitate individualized predictions regarding the benefits and risks of pharmacological and surgical treatments.
The authors identify several hurdles to clinical implementation, including the need for better data quality control, continuous model validation, and improved transparency. They also note a need for clearer accountability, supportive policies, and cost coverage. While these technologies offer significant potential for precision medicine by modeling complex associations, the current evidence focuses on technical capabilities rather than specific trial outcomes.
How this fits prior evidence
This systematic review addresses a gap in the technological infrastructure of cardiovascular care. While prior evidence has established the efficacy of pharmacological interventions like PCSK9 inhibitors and lifestyle modifications such as the Mediterranean diet for risk reduction, this finding explores the role of machine learning and multi-omics to improve diagnosis and individualized treatment planning.
Researchers reviewed how machine learning and multi-omics technologies can improve the way we manage cardiovascular disease. These tools look at complex biological data to help doctors make more precise decisions. The goal is to move toward precision medicine, where treatments are tailored specifically to each patient's unique profile.
The review found that these technologies can assist with early detection and helping doctors tell different conditions apart. They also provide a framework for predicting risks in high-risk populations. This includes better ways to predict how well a patient might respond to specific surgeries or medications before they begin treatment.
Because this is a systematic review of technology rather than a clinical trial, the results are not yet ready to change daily medical practice. There are still hurdles to overcome, such as ensuring data quality and establishing clear policies for costs and accountability. These tools currently offer technical support for doctors rather than replacing standard care.
What this means for you:
Machine learning and multi-omics can help predict risks and tailor treatments for cardiovascular disease patients.
Common questions
How does machine learning help with heart disease?
Machine learning combined with multi-omics can assist with definitive diagnosis, early detection, and assessing the severity of cardiovascular disease. These tools allow for more noninvasive, objective, and rapid evaluations to help doctors understand a patient's condition more clearly.
Can these technologies predict treatment success?
Yes, these technologies can provide an individualized prediction of the benefits and risks of both pharmacological and surgical treatments. This helps healthcare providers determine which specific interventions are most likely to work for a particular patient with cardiovascular disease.
Is this technology ready to replace standard heart care?
Not yet. The review highlights that while these tools offer great technical support for precision medicine, there are still challenges regarding data quality, model validation, and policy coverage before they can be fully integrated into routine clinical practice.
Cardiovascular disease remains a major global health burden. Owing to its complex pathogenesis and marked clinical heterogeneity, conventional one-size-fits-all strategies often yield limited benefit for a substantial proportion of patients. Precision medicine advocates individualized management based on patients' clinical and molecular characteristics to improve outcomes. In this context, multi-omics and machine learning provide critical technical support for precision medicine: multi-omics can capture the full spectrum of cardiovascular disease from molecular alterations to phenotypic manifestations, while machine learning is well-suited to modeling complex associations between high-dimensional, nonlinear omics data and clinical outcomes. Their integration has therefore opened new avenues for the precise management of cardiovascular disease. This review systematically summarizes recent advances in applying machine learning and multi-omics to precision cardiovascular medicine, with a focus on three core domains: diagnosis, risk prediction, and treatment response prediction. In diagnosis, these approaches can assist with definitive diagnosis, early detection, differential diagnosis, and severity assessment, thereby enabling more noninvasive, objective, rapid, and precise evaluation of cardiovascular disease. In risk prediction, they support a comprehensive framework spanning primary prevention, secondary prevention, short-term risk stratification, and screening of high-risk populations, allowing risk management across the full disease course and across diverse patient groups. In addition, they enable individualized prediction of the benefits and risks of pharmacological and surgical treatments, thereby informing therapeutic decision-making. To facilitate clinical translation, several challenges remain particularly important, including data quality control, continuous model validation, improved transparency, clarification of responsibility and accountability, and supportive policies regarding implementation and cost coverage.
